[Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
作者信息
García de Yébenes J, Avila C, Bazán E, García E, Gervás J, Maseda C, Mena M, Muradas V, Ramos J A
出版信息
Med Clin (Barc). 1982 Apr 1;78(7):259-64.
PMID:7087591
Abstract
摘要
相似文献
1
2
[Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].[左旋多巴单独治疗及左旋多巴与多巴脱羧酶抑制剂联合治疗的长期治疗方面]
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1982 Oct-Dec;27(4):261-70.
3
4
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.左旋多巴和脱羧酶抑制剂治疗老年帕金森病患者的患者获益情况。
Pharmatherapeutica. 1985;4(2):132-40.
5
6
[The L-dopa test in Parkinson's disease].[帕金森病的左旋多巴试验]
Rev Neurol (Paris). 1985;141(5):413-5.
7
[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].溴隐亭与多潘立酮治疗帕金森病的长期疗效（作者译）
Rev Neurol (Paris). 1981;137(1):49-51.
8
[Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Nervenarzt. 1981 Feb;52(2):116-20.
9
L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?多巴脱羧酶缺乏导致的左旋多巴抵抗性帕金森症？
Ann Neurol. 1981 Jul;10(1):64-5. doi: 10.1002/ana.410100117.
10
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].[脱羧酶抑制剂与左旋多巴联合用于帕金森病的治疗]
Rev Prat. 1974 Mar 11;24(15):1211-2, 1215-6, 1219.
Zotero 插件